Investigational CDK4/6 Inhibitor Abemaciclib is Active Against a Range of Cancer Types
The investigational anticancer therapeutic abemaciclib (formerly LY2835219), which targets CDK4 and CDK6, showed durable clinical...
FDA Expands Use of Molecularly Targeted Therapeutic for Lung Cancer
The U.S. Food and Drug Administration (FDA) recently approved the use of molecularly targeted therapeutic afatinib (Gilotrif) for...
